A Joint Study of Features and Treatment of Urogenital Disorders in Japan and People's Republic of China

1990年5月开始了一项关于泌尿生殖系统疾病的特征和治疗的联合研究。北京医学院泌尿外科年平均住院病人400例。本研究旨在探讨浸润性膀胱癌新辅助化疗、去势加化疗治疗晚期前列腺癌及先天畸形的发生率，结果如下：（1）浸润性膀胱癌新辅助化疗8例，采用顺铂动脉灌注法;所有手术切除材料的患者均显示部分肿瘤消退。2）对7例前列腺癌骨转移患者行去势术联合IFAP（异环磷酰胺、5-FU、阿霉素、顺铂）化疗，观察其疗效。这种联合治疗不仅有效缓解疼痛，而且加速降低血清肿瘤标志物水平。两所医院住院患者先天畸形发生率均为8%。隐睾和尿道下裂也是最常见的先天性畸形。

A joint study of features and treatment of urogenital disorders was started in May, 1990. Mean inpatients number is 400 per year at urological service, Beijing Medical School. Purposes of this study are to evaluate the neoadjuvant chemotherapy of invasive bladder cancer, castration plus chemotherapy for the advanced prostatic cancer and the incidence of congenital anomaly.Results are as follows :1) For neoadjuvant chemotherapy of invasive bladder cancer, 8 patients were treated with CDDP arterial instillation method. Partial tumor regression was revealed in all patients with surgically resected materials. It seems that this therapy is also available in China because of tumor regression effect with low toxicity.2) 7 cases of prostatic cancer with bone metastasis were treated with castration and IFAP (Ifosphamide, 5FU, Adriacin and CDDP) chemotherapy. This combination therapy is effective with not only pain relief but also accelerated reduction of serum tumor markers levels. Long follow up is needed.3) The incidence of congenital anomaly in inpatients is 8% in both institutes. And it is also the same situation that undescended testis and urethral hypospadia are the most common congenital anomalies.